Overview
- Provides a comprehensive review on pharmacokinetics, pharmacodynamics and toxicity of polymyxins
- Clarifies the confusing definitions of potency of colistin used in different parts of the world
- Reviews strategies of discovery of novel polymyxin-like antibiotics
Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 1145)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (21 chapters)
-
Front Matter
Keywords
About this book
This volume is the first-ever complete treatise on polymyxins and presents the most comprehensive and up-to-date reviews of all major research and clinical topics from chemistry, microbiology, pharmacology, clinical use, to drug discovery. All chapters were written by internationally leading researchers and clinicians in the field.
It is our wish that readers discover the importance of polymyxin structure in relation to the mechanisms of activity, resistance and toxicity. We emphasized that reliable analytic methods for polymyxins are critical when investigating their pharmacokinetics (PK) and pharmacodynamics (PD). The complicated dose definitions and different pharmacopoeial standards have already compromised the safe use of polymyxins in patients. Therefore, informed by the latest pharmacological information, scientifically-based dosing recommendations have been proposed for intravenous polymyxins. Considering the PK/PD limitations and potential development of resistance, polymyxin combinations are encouraged; however, the current literature has not shown definite microbiological benefits, possibly because most clinical studies to date overlooked key PK/PD principles. Nephrotoxicity is the major dose-limiting factor and it is imperative to elucidate the mechanisms and develop novel approaches to minimize polymyxin-associated toxicities. In addition, the anti-endotoxin effect of polymyxins supports their clinical use to treat Gram-negative sepsis. Fortunately, the discovery of new-generation polymyxins with wider therapeutic windows has benefited from the latest achievements in polymyxin research.
This book provides extensive pharmacological information on polymyxins to infectious diseases clinicians, pharmacists, clinical microbiologists, antimicrobial pharmacologists, and pharmaceutical scientists, and is an essential read for those who aim to develop novel polymyxins and improve their clinical use as a last-line defense against Gram-negative ‘superbugs’.
Editors and Affiliations
Bibliographic Information
Book Title: Polymyxin Antibiotics: From Laboratory Bench to Bedside
Editors: Jian Li, Roger L. Nation, Keith S. Kaye
Series Title: Advances in Experimental Medicine and Biology
DOI: https://doi.org/10.1007/978-3-030-16373-0
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer Nature Switzerland AG 2019
Hardcover ISBN: 978-3-030-16371-6Published: 12 August 2019
eBook ISBN: 978-3-030-16373-0Published: 30 July 2019
Series ISSN: 0065-2598
Series E-ISSN: 2214-8019
Edition Number: 1
Number of Pages: VIII, 366
Number of Illustrations: 45 b/w illustrations, 44 illustrations in colour
Topics: Bacteriology, Pharmacotherapy, Drug Resistance